<DOC>
	<DOCNO>NCT00778830</DOCNO>
	<brief_summary>This open-label , non-randomized , multicenter Phase II study evaluate folinic acid + fluorouracil + irinotecan ( FOLFIRI ) plus cetuximab ( Erbitux ) folinic acid + fluorouracil + oxaliplatin ( FOLFOX ) plus cetuximab first-line therapy patient KRAS wild-type metastatic colorectal cancer . Only subject k-ras oncogene ( KRAS ) wild-type tumor eligible . Efficacy assess every 8 week . Treatment continue progressive disease unacceptable adverse event occur . After end study treatment , information anticancer treatment survival collect every 3 month .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy FOLFIRI Plus Cetuximab FOLFOX Plus Cetuximab First-line Therapy Subjects With KRAS Wild-type Metastatic Colorectal Cancer ( APEC-Study )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed write informed consent Inpatient outpatient subject , 18 year age Diagnosis histologically confirm adenocarcinoma colon rectum Metastatic disease ( M1 ) Life expectancy least 12 week Presence least 1 measurable index lesion ( lie irradiate area ) compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 study entry Effective contraception male female subject risk conception exists White blood cell count great equal ( &gt; = ) 3,000 per cubic millimeter ( /mm^3 ) neutrophils &gt; =1,500/mm3 , platelet count &gt; =100,000/mm3 , hemoglobin &gt; =5.6 millimole per liter ( mmol/L ) ( 9 gram per deciliter [ g/dL ] ) Total bilirubin less equal ( &lt; = ) 1.5 x upper reference range Aspartate aminotransferase ( AST ) &lt; =2.5 x upper reference range , &lt; =5 x upper reference range case liver metastasis Serum creatinine &lt; =1.5 x upper reference range Recovery relevant toxicity previous treatment study entry KRAS wildtype status tumor tissue Previous chemotherapy colorectal cancer except adjuvant treatment terminate &gt; 6 month start treatment study Radiotherapy , surgery ( exclude prior diagnostic biopsy ) investigational drug 30 day start treatment study Concurrent chronic systemic immune therapy , target therapy , antivascular endothelial growth factor ( VEGF ) therapy , epidermal growth factor receptor ( EGFR ) pathway target therapy indicate study protocol Concurrent hormone therapy indicate study protocol except physiologic replacement contraception Known hypersensitivity reaction component study treatment Pregnancy ( absence confirm beta human choriongonadotrophin [ betahCG ] test ) lactation period Brain metastasis and/or leptomeningeal disease ( know suspect ) Clinically relevant coronary artery disease , history myocardial infarction last 12 month , high risk uncontrolled arrhythmia Acute subacute intestinal occlusion history inflammatory bowel disease Peripheral neuropathy &gt; grade 1 Previous malignancy colorectal cancer last 5 year except basal cell cancer skin preinvasive cancer cervix Known alcohol drug abuse Medical psychological condition would permit patient complete study sign inform consent Participation another clinical study within past 30 day Significant disease , investigator 's opinion , would exclude patient study Legal incapacity limit legal capacity KRAS mutate status tumor tissue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>mCRC</keyword>
</DOC>